Vale SA vs Vir Biotechnology Inc. Common Stock — how do they compare? Vale SA trades at $13.19 (market cap $57.30B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Vale SA is far larger — about 31.8× Vir Biotechnology Inc. Common Stock's market cap, and Vale SA pays a 8.9% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vale SA for 110 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| VALE | VIR | |
|---|---|---|
Market Cap | $57.30B | $1.80B |
Volume | 25,010,417 | 1,782,836 |
Sector | Basic Materials | Health |
52-Week High | $17.82 | $11.78 |
52-Week Low | $11.10 | $5.12 |
Typical Hold Time | 110 Days | 0 Days |
Enterprise Value | $73.54B | $1.36B |
Dividend Yield | 8.9% | — |
Signals from Pluang's Aura AI — not financial advice
VALE trades at $13.21, down 2.29% today, with a bearish technical signal and three consecutive quarterly EPS misses. The stock shows mixed fundamentals with a P/E of 26.74 and net income margin of 5.11%, while cash flow improved to $2.42B in 2025. Recent news highlights pressure from US steel expansion plans and rising operational costs.
Analyst consensus is cautious with 57% hold ratings and a $15.93 price target, suggesting 21% upside. Key risks include iron ore price volatility, Brazilian regulatory exposure, and margin compression from cost inflation. The base metals segment growth provides some diversification support amid cyclical headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →